Endocrinology 156 (9), 31223136 (2015)
Biomed Opt Express 4(2):307321 Zachos KA, Choi J, Godin O, Chernega T, Kwak HA, Jung JH et al (2024) Mitochondrial biomarkers and metabolic syndrome in bipolar disorder
GLP-1 based medicines usually have glucose-dependent effects, but hypoglycemia risk can rise when they are used with insulin or insulin-releasing medicines such as sulfonylureas
If you look at the studys charts, which I thought were striking, you see that you might regain more weight and end up worse off than you were before, says Rozalina McCoy, an endocrinologist and internist at the University of Maryland School of Medicine, who was not involved in the study
At week 26, LDL-C was reduced by 19.0% (-36.0% to -1.9%, p=.029) in the tirzepatide 15 mg group compared to placebo while it was reduced by 17.8% (-33.7% to -2.0%, p= 0.028) in the dulaglutide 1.5 mg group compared to placebo though differences between the 2 medications were not seen [60]
